" class="no-js "lang="en-US"> Genoscience Pharma - Medtech Alert
Tuesday, September 23, 2025
Genoscience Pharma | Pharmtech Focus

Genoscience Pharma

About Genoscience Pharma

Genoscience Pharma

Genoscience Pharma was founded in 2001 by Pr Philippe Halfon, a world renowned medical expert on viral diseases, especially on Human Immunodeficient Virus (HIV) and Hepatitis C Virus (HCV).
The company was initially focused on the development of anti-HCV agents. Two protease inhibitors were thus developed and out-licensed to BioLineRX.
A new scientific direction was taken in 2012 after the discovery of a new chemical family: autophagy inhibitors. Following promising preliminary in vitro and in vivo results from these small molecules, including against cancer stem cells, Genoscience Pharma has decided to take the opportunity to make the difference in Oncology, especially in cancers where medical needs are still unmet. Now, Genoscience Pharma is a clinical stage biopharmaceutical company focused on translating novel scientific insights into medicines for patients with cancer.

Related Story

Genoscience Pharma receives FDA Orphan Drug Designation for ezurpimtrostat to treat HepatoCellular Carcinoma (HCC)

February 1 2023

Genoscience Pharma, a clinical-stage biotech company developing unique lysosomotropic drug candidates for the treatment of […]

Genoscience Pharma Licenses GNS561, its PPT-1 Inhibitor, to GENFIT in Cholangiocarcinoma Indication in US/Canada and Europe

December 17 2021

Genoscience Pharma, a clinical stage biotechnology company developing unique lysosomotropic drug candidates for the treatment of […]